Replies to post #152535 on Anavex Life Sciences Corp (AVXL)

[poguemahone]

Do we have any idea what % of the AD population A2-73 could potentially address with this targeted approach? 20%? 30%?

Does anyone have some type of educated guess? I'm hoping we might be able to target at least 25% of the population, or 1 in 4 patients.